clinical trial · NCT04654468
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition
Hoffmann-La Roche·phase3·active not recruiting·n = 51
Paroxysmal Nocturnal HemoglobinuriaCrovalimab
brief summary
This study will enroll participants aged 12 years or older with a body weight ≥ 40 kilograms (kg) diagnosed with PNH who have not been previously treated with complement inhibitor therapy. Approximately 50 participants will be treated with Crovalimab for at least 24 weeks.
started
Mar 17, 2021
primary completion
Feb 10, 2022
completion
Dec 31, 2026
last updated
Feb 11, 2026
official title
A Phase III, Multicenter, Single Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol